Syntis Bio
Syntis Bio raises $33M Series A
Syntis Bio: Series A Funding Round
Syntis Bio has successfully raised $33M in Series A funding.
Company Overview
Developing oral therapies for obesity diabetes and rare diseases
Funding Details
The Series A round was led by Cerberus Ventures.
Company Information
- Headquarters: Cambridge, MA
- Founded: 2022
- Employees: 50+
- Category: HealthTech
Investment
Syntis Bio plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Cerberus Ventures: Verified investor in Series A
Company Info
Investors (1)
Share
Related Reports
Abridge Raises $150M Series C to Transform HealthTech
Abridge has secured $150M Series C in funding to accelerate growth and innovation in the healthtech sector. Medical AI scribe platform automatically documenting patient-provider conversations and generating clinical notes...
Innovaccer Raises $275M Series F to Transform HealthTech
Innovaccer has secured $275M Series F in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform unifying patient data and providing analytics for value-based care and population health manage...
Truveta Raises $95M Series B to Transform HealthTech
Truveta has secured $95M Series B in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform aggregating de-identified patient records to accelerate medical research and drug development...
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free